Literature DB >> 9394328

Colchicine myopathy in renal transplant recipients on cyclosporin.

D Ducloux1, V Schuller, C Bresson-Vautrin, J M Chalopin.   

Abstract

Few data are available about the muscle status in renal transplant recipients. Moreover, the list of myotoxic drugs is growing longer and some of them are likely to be prescribed in renal transplant patients. These conditions may act as confounding factors in case reports of both cyclosporin and colchicine myopathies. Moreover no study has evaluated the frequency of myopathy in patients on both colchicine and cyclosporin. We conducted a retrospective study including all renal transplant recipients followed in our unit in whom colchicine was prescribed since January 1994. Clinical and biological data of patients on both colchicine and cyclosporin were analysed. Secondly case subjects were compared with matched controls not receiving colchicine but cyclosporin. Ten patients received colchicine in association with cyclosporin. Five patients (50%) experienced muscular symptoms and when performed, muscular histology showed vacuolar myopathy. All five patients improved after colchicine withdrawal. Cases with and without muscular symptoms did not differ in age, transplant duration, and serum creatinine level. Mean duration of colchicine therapy was 12.2 +/- 4.4 months in cases with muscular symptoms and 6.8 +/- 4.6 months in cases without muscular symptoms (P < 0.05). No control complained of either muscular pain nor weakness (P < 0.0005). Only one patient (3.3%) had elevated serum creatine phosphokinase concentration (P < 0.0005). We conclude that myopathy is very frequent in patient on both colchicine and cyclosporin. Muscular symptoms improve in all patients after colchicine withdrawal.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9394328     DOI: 10.1093/ndt/12.11.2389

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  7 in total

Review 1.  Gout in solid organ transplantation: a challenging clinical problem.

Authors:  Lisa Stamp; Martin Searle; John O'Donnell; Peter Chapman
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 2.  Gout and organ transplantation.

Authors:  Lisa K Stamp; Peter T Chapman
Journal:  Curr Rheumatol Rep       Date:  2012-04       Impact factor: 4.592

3.  Musculoskeletal affections among kidney recipients: prevalence and risk predictors.

Authors:  Alia M Atallah; Seif M Farag; Mohamed K Senna; Mohamed A Ghoneim
Journal:  Rheumatol Int       Date:  2008-04-29       Impact factor: 2.631

4.  Fatal toxic myopathy attributed to propofol, methylprednisolone, and cyclosporine after prior exposure to colchicine and simvastatin.

Authors:  Lisa Francis; Eduardo Bonilla; Ekaterina Soforo; Hom Neupane; Hassan Nakhla; Christine Fuller; Andras Perl
Journal:  Clin Rheumatol       Date:  2007-07-13       Impact factor: 2.980

5.  Colchicine-induced myoneuropathy in a cyclosporine-treated renal transplant recipient.

Authors:  Kyungmin Huh; Ji Young Joung; Hyemin Jeong; Dongmo Je; Yoon Young Cho; Hye Ryoun Jang; Wooseong Huh
Journal:  Kidney Res Clin Pract       Date:  2013-05-23

6.  Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials.

Authors:  Sarah Stewart; Kevin Chih Kai Yang; Kate Atkins; Nicola Dalbeth; Philip C Robinson
Journal:  Arthritis Res Ther       Date:  2020-02-13       Impact factor: 5.156

Review 7.  Prevalence of Musculoskeletal Manifestations in Adult Kidney Transplant's Recipients: A Systematic Review.

Authors:  Adla B Hassan; Kanz W Ghalib; Haitham A Jahrami; Amgad E El-Agroudy
Journal:  Medicina (Kaunas)       Date:  2021-05-23       Impact factor: 2.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.